[
  {
    "query_id": "0x6b5279432741b9a38d6812526eb5e2243e0c0fde085d818626df97d9c65b32e3",
    "transaction_hash": "0xace067d4c7d2fda123f1186e693bfdc29057bffe98ea06e4d42dfdfe64f9210a",
    "block_number": 72972144,
    "request_transaction_block_time": 1750361204,
    "ancillary_data": "q: title: FDA approves Gilead's lenacapavir for treating HIV?, description: This market will resolve to \"Yes\" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Gilead Sciences' new biologics license application (BLA) for lenacapavir as a treatment for Human Immunodeficiency Virus (HIV) by June 19, 2025, 11:59 PM ET. Otherwise, this market will resolve to \"No.\"\n\nThis market will immediately resolve to \"No\" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application.\n\nConditional approvals may include post-marketing requirements or commitments and still qualify.\n\nThe primary resolution source will be official information from the FDA, however a consensus of credible reporting may also be used. \n market_id: 553036",
    "ancillary_data_hex": "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",
    "resolution_conditions": "res_data:p1: 0, p2: 1, p3: 0.5. Where p1 corresponds to No, p2 to Yes, p3 to unknown/50-50.",
    "proposed_price": 1000000000000000000,
    "proposed_price_outcome": "p2",
    "resolved_price": null,
    "resolved_price_outcome": null,
    "request_timestamp": 1750187578,
    "expiration_timestamp": 1750368404,
    "creator": "0x6A9D222616C90FcA5754cd1333cFD9b7fb6a4F74",
    "proposer": "0x0DB5Aea9F41Ce8398104e9d4694cfb18f146C493",
    "bond_currency": "0x2791Bca1f2de4661ED88A30C99A7a9449Aa84174",
    "proposal_bond": 500000000,
    "reward_amount": 5000000,
    "updates": [
      "(1750361050, b'On June 18, 2025, lenacapavir (Yeztugo) received FDA approval as a treatment for HIV via a New Drug Application (NDA). This qualifies as approval for the purposes of this market.')"
    ],
    "condition_id": "0x11039e885cdc6019a73715569da44dd3577debdaf54a7a85f107e345dd5cc97d",
    "tags": [
      "Science",
      "Tech",
      "drug",
      "Lenacapavir"
    ],
    "icon": "https://polymarket-upload.s3.us-east-2.amazonaws.com/fda-approves-mercks-clesrovimab-infant-rsv-prevention-mk1654-UwIlSPqRRYN3.jpg",
    "end_date_iso": "2025-06-19T00:00:00Z",
    "game_start_time": "2025-06-19T19:24:00Z",
    "tokens": [
      {
        "token_id": "74791633337136725287146513478286073837277086591109537091868763217922592268760",
        "outcome": "Yes",
        "price": 0.5,
        "winner": false
      },
      {
        "token_id": "100245270205360204116456694799691889005020264135408401386104160729238938332731",
        "outcome": "No",
        "price": 0.5,
        "winner": false
      }
    ],
    "neg_risk_market_id": "",
    "neg_risk_request_id": ""
  }
]